Lung Cancer | Specialty

EC Approves Crizotinib for ROS1-Positive NSCLC

September 1st 2016

The European Commission has approved crizotinib (Xalkori) as a treatment for patients with advanced ROS1-positive non–small cell lung cancer.

Atezolizumab Improves Survival in Phase III Lung Cancer Study

September 1st 2016

Atezolizumab (Tecentriq) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

September 1st 2016

Dr. Pennell on Importance of EGFR Testing in NSCLC

August 31st 2016

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

Dr. Leora Horn on Toxicities With Immunotherapy in Lung Cancer

August 31st 2016

FDA Submission Completed for Brigatinib in ALK-Positive NSCLC

August 30th 2016

A new drug application has been submitted for brigatinib (AP26113) as a potential treatment for patients with advanced ALK-positive non–small cell lung cancer following resistance or intolerance to crizotinib (Xalkori).

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

August 30th 2016

Dr. Suresh S. Ramalingam on Optimizing Immunotherapies in Lung Cancer

August 26th 2016

Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC

August 26th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.

Leptomeningeal Metastases More Common in EGFR-Mutant NSCLC

August 22nd 2016

In patients with EGFR-mutant non–small cell lung cancer, the incidence of leptomeningeal metastases is found to be common; moreover, the optimal treatment for this occurrence was determined to be tyrosine kinase inhibitors.

Dr. Henricus de Koning on Screening in NSCLC

August 19th 2016

Dr. Baas on Next Steps in the Treatment of Mesothelioma

August 19th 2016

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

August 18th 2016

Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer

August 15th 2016

Biomarkers, such as immune cell PD-L1 expression, mutational burden, and immune system activation should be investigated further to clarify the mechanisms behind response and nonresponse to immunotherapy in patients with lung cancer.

Bunn Discusses Frontline Nivolumab NSCLC Results, Issues With PFS Endpoint

August 11th 2016

Paul A. Bunn Jr, MD, discusses the meaning of the CheckMate-026 results with frontline nivolumab in NSCLC and issues with the trial's primary endpoint of progression-free survival.

Biomarker-Driven Trials Set Pace in Lung Cancer

August 11th 2016

Biomarker-driven trials that include multiple substudies represent a new approach for investigating which patients with lung cancer are more likely to respond to different targeted therapies and are helping to set the pace throughout the oncology field.

Optimal Therapy Sequence Continues to Evolve for Advanced NSCLC

August 9th 2016

The past few years have seen rapid evolution in the treatment and handling of advanced non–small cell lung cancer, prompting questions on how to optimize immunotherapies and targeted agents as well as incorporate biomarker testing.

Liquid Biopsies Likely to Fill Many Roles in NSCLC Treatment

August 9th 2016

The optimal use of emerging assays that characterize molecular abnormalities from plasma in late-stage non–small cell lung cancer will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.

Selumetinib Fails to Improve PFS in Phase III Lung Cancer Study

August 9th 2016

The combination of selumetinib and docetaxel failed to improve survival compared with docetaxel alone as a second-line treatment for patients with KRAS-mutant locally advanced or metastatic non–small cell lung cancer.